The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/200279

Please be advised that this information was generated on 2020-03-10 and may be subject to change.
Observer variability of reference tissue selection for relative cerebral blood volume measurements in glioma patients

Marcel T. H. Oei 1 · Frederick J. A. Meijer 1 · Jan-Jurre Mordang 1 · Ewoud J. Smit 1 · Albert J. S. Idema 2 · Bozena M. Goraj 1 · Hendrik O. A. Laue 3 · Mathias Prokop 1 · Rashindra Manniesing 1

Received: 9 October 2017 / Revised: 27 December 2017 / Accepted: 23 January 2018 / Published online: 23 March 2018 © The Author(s) 2018

Abstract
Objectives To assess observer variability of different reference tissues used for relative CBV (rCBV) measurements in DSC-MRI of glioma patients.

Methods In this retrospective study, three observers measured rCBV in DSC-MR images of 44 glioma patients on two occasions. rCBV is calculated by the CBV in the tumour hotspot/the CBV of a reference tissue at the contralateral side for normalization. One observer annotated the tumour hotspot that was kept constant for all measurements. All observers annotated eight reference tissues of normal white and grey matter. Observer variability was evaluated using the intraclass correlation coefficient (ICC), coefficient of variation (CV) and Bland-Altman analyses.

Results For intra-observer, the ICC ranged from 0.50–0.97 (fair–excellent) for all reference tissues. The CV ranged from 5.1–22.1 % for all reference tissues and observers. For inter-observer, the ICC for all pairwise observer combinations ranged from 0.44–0.92 (poor–excellent). The CV ranged from 8.1–31.1 %. Centrum semiovale was the only reference tissue that showed excellent intra- and inter-observer agreement (ICC>0.85) and lowest CVs (<12.5 %). Bland-Altman analyses showed that mean differences for centrum semiovale were close to zero.

Conclusion Selecting contralateral centrum semiovale as reference tissue for rCBV provides the lowest observer variability.

Key Points
- Reference tissue selection for rCBV measurements adds variability to rCBV measurements.
- rCBV measurements vary depending on the choice of reference tissue.
- Observer variability of reference tissue selection varies between poor and excellent.
- Centrum semiovale as reference tissue for rCBV provides the lowest observer variability.

Keywords Cerebral blood volume · Observer variation · Perfusion imaging · Magnetic resonance angiography · Glioma

Abbreviations

(NA)GM (Normal-appearing) grey matter
(NA)WM (Normal-appearing) white matter
(r)CBV (relative) Cerebral blood volume

CV Coefficient of variation
DSC-MRI T2*-weighted dynamic susceptibility contrast-enhanced MR imaging
GE-EPI Gradient echo-echo planar imaging
ICC Intraclass correlation coefficient
ROI Region of interest
T1w/T2w T1-weighted/T2-weighted

Introduction

T2*-weighted dynamic susceptibility contrast-enhanced MR imaging (DSC-MRI) has been shown to be useful in evaluating brain neoplasms. With DSC-MRI, T2*-weighted echo planar images are acquired that measure the signal intensity...
change over time after the injection of a bolus of a paramagnetic contrast agent. The change in relaxation rate ($\Delta R2^*$) can be calculated from the signal intensity and is proportional to the contrast agent in the tissue. Cerebral blood volume (CBV) is a parameter that can be measured with DSC-MRI, and is proportional to the area under the curve of $\Delta R2^*(t)$. Studies have used CBV to differentiate between low- and high-grade gliomas [1, 2], to differentiate tumour progression from pseudo-progression [3], and to assess treatment response to anti-angiogenic drug therapy [4–6]. CBV measurements may show high variability. Values vary due to different image acquisition protocols and post-processing methods and also due to physiological differences in the patients such as cardiac output and haematocrit values. This makes it difficult to compare CBV among patients and studies. Therefore, CBV is typically normalized to a reference tissue. The relative CBV (rCBV) is calculated by the CBV in the region of interest (e.g. tumour hotspot) divided by the CBV of an internal reference tissue for normalization. A typical reference tissue is the contralateral normal-appearing white matter (NAWM) or the normal-appearing grey matter (NAGM).

Different reference tissues are used in the literature, including normal-appearing white or grey matter (contralateral or ipsilateral) [7], the contralateral NAWM [2, 8], the contralateral NAGM [9], contralateral thalamus [10] or contralateral centrum semiovale [11]. Most studies do not describe their exact location or give an exact definition, but it is known for instance that CBV values of grey matter are higher than CBV values of white matter [12].

The rCBV is subject to observer variability when the regions of interests (ROIs) are manually annotated. Variability can be reduced by the use of (semi-)automated methods [13–15], but despite their existence, they are not commonly available, and manual annotations of the reference tissue by an experienced radiologist is still common practice [16, 17] for which a reliable and reproducible reference ROI is necessary. Wetzel et al. [18] investigated the observer variability of annotating the tumour hotspot while keeping the internal reference tissue constant. The authors did not study the observer variability of annotating the reference tissue.

Thus, the purpose of this study was to assess the observer variability of rCBV measurements depending on the choice of the reference tissue that is used for normalization in DSC-MRI of glioma patients.

**Materials and methods**

**Patient selection**

For this retrospective study informed consent was waived. Between 2006 and 2008 our institution participated in a European project called eTumour. Patients presenting with symptoms suggestive of brain tumour, newly diagnosed and untreated brain tumours were prospectively included. One day before surgery they underwent conventional MR, MR spectroscopy and MR perfusion (DSC-MRI) imaging. Our institution included 98 subjects with brain tumours. Further details of the eTumour project can be found in Julia-Sape et al. [19].

The patient selection criteria to select patients from the eTumour database were as follows: (1) Subjects with a histopathologically confirmed diagnosis of glioma was available; (2) subjects did not have surgical resection, biopsy or radiation therapy before DSC-MR imaging was performed; and (3) subjects were 18 years or older. Subjects were excluded if the DSC-MRI was technically inadequate due to motion and susceptibility artifacts.

In total 44 consecutive patients (17 female; 27 male; median age, 58 years; range, 21–79 years) were included. The patients were diagnosed with pathologically proven gliomas (one subependymal giantcell astrocytoma, five low-grade astrocytomas, two low-grade oligoastrocytomas, one anaplastic astrocytoma, five anaplastic oligodendrogliaoms and 30 glioblastoma multiforme).

All tumours were located supratentorially.

**MR imaging**

MR sequences were acquired on a 3T system (MAGNETOM Trio; Siemens, Erlangen, Germany). The acquisition protocol included an axial T2-weighted (T2w) sequence (repetition time and echo time TR/TE = 4,040/102 ms) or an axial transverse fluid-attenuated inversion recovery (FLAIR) sequence (TR/TE 13,050/103 ms) and an axial T1-weighted (T1w) spin-echo sequence (TR/TE 2,300/4.7 ms) performed before and after intravenous administration of gadoteratemegumine (Dotarem; Guerbet, Paris, France). The axial contrast-enhanced T1w spin-echo sequence was performed after acquisition of DSC-MRI.

DSC-MRI was performed with a gradient-echo echoplanar imaging sequence (GE-EPI) during the first pass of a (0.1 mmol/kg) bolus of gadoteratemegumine at a rate of 2.5 ml/s. Imaging parameters were as follows: TR/TE 1,670/45 ms; FOV 230×230 mm; matrix 128×128; voxel size 1.8×1.8×5.0 mm$^3$; intersection gap 30 %; flip angle 90°; signal bandwidth 1,346 Hz/x. Fifteen axial sections were obtained through the brain.

**Observers**

One observer (MTHO, with 3 years of experience) annotated the tumour hotspot according to the method described by
Wetzel et al. [18] and did not participate in annotating the reference tissues. Three observers (FJAM and BMG, certified neuroradiologists with 10 and 30 years of experience, respectively, and EJS, a resident radiology) independently performed all measurements for the reference tissues. The observers were blinded to patient history and diagnosis. The observers underwent a training session with five training cases, which were excluded in the final evaluation in order to limit performance bias.

**Image analysis**

The DSC-MR images were processed on a dedicated in-house developed workstation (Cirrus Brain MR, version 7335, Radboudumc, Nijmegen, The Netherlands). Processing consisted of image registration of DSC-MRI to the T1w image, followed by calculation of the CBV perfusion map [20]. The Weisskoff correction method was used to correct for T1 leakage effects [21, 22]. The DSC-MR image, corresponding CBV map and conventional MR images (T1w before and after contrast, T2w or FLAIR) were made available in the workstation to the observers.

One observer (MTHO) defined the tumour hotspot following Wetzel et al. [18] by annotating four to six circular ROIs of 25 mm² in the area of the tumour hotspot and selecting the ROI with the highest CBV value. This region was then kept constant for all observers in the subsequent normalization step. Defining the tumour hotspot was done in a separate session and care was taken to avoid areas of necrosis, cysts, or non-tumour macro-vessels.

To evaluate the influence normalization for calculating rCBV, all observers were asked to place a reference ROI in a homogenous region at the contralateral side of approximately 25 mm² in the:

- NAWM on the axial section deemed most appropriate by the observers
- NAGM on the axial section deemed most appropriate by the observers
- NAWM on the same axial section as the tumour ROI
- NAGM in the putamen
- frontal NAWM
- parietal NAWM
- NAGM in the thalamus
- centrum semiovale.

Large vessels and tumour-suspicious regions were avoided. rCBV was calculated by dividing the tumour CBV by the CBV of the reference tissue. Figure 1 shows an example of ROI placement in the regions listed above.

**Statistical analysis**

Statistical analyses were performed with IBM SPSS Statistics version 20 (SPSS Inc., Chicago, IL, USA). The mean and standard deviation of the rCBV measurements were determined per reference tissue, evaluation session and observer. Normal distribution was tested using the Shapiro-Wilk test. A paired t-test was used to compare the rCBV measurements between the two evaluations for every observer and all reference tissues, with p<0.05 considered statistically significant.

For the statistical analyses of the observer variability, the coefficient of variation (CV), intraclass correlation coefficient (ICC) and Bland-Altman analyses were used. The CV was calculated for the rCBV for every reference tissue, and every observer. The ICC is reported with a 95 % confidence interval where ICC <0.4 was considered poor agreement, ICC 0.40–0.59 was considered fair agreement, ICC 0.60–0.74 was considered good agreement, and ICC >0.74 was considered excellent agreement [23]. Bland-Altman analyses were expressed as the mean difference, standard deviation and 95 % limits of agreement.

**Intra-observer variability**

The observers repeated the rCBV measurements after 2 weeks or longer (up to a month) to assess the intra-observer variability. The measurements were made on the same dataset but in a different random order of presentation to limit recall bias. The statistical analyses were calculated for rCBV measurements between the two evaluations of an observer, for each reference tissue. A two-way mixed ICC model, with absolute agreement, single measures and a 95 % confidence interval was used.

**Inter-observer variability**

The statistical analyses were calculated for every pairwise combination of observers to assess the inter-observer variability. Only the rCBV measurements of the first evaluation for every reference tissue and observer were used. A two-way random ICC model, with absolute agreement, single measures and a 95 % confidence interval was used.

**Results**

The mean and standard deviation of the rCBV measurements for all observers are shown in Table 1. There was no statistically significant difference between the rCBV measurements of the two evaluations of all tissues, except for observer 1 in NAWM tumour.
Intra-observer variability

The ICC, CV and Bland-Altman analysis for intra-observer variability are summarized in Table 2. The ICC ranged from 0.50 to 0.97 for all tissues, indicating fair to excellent agreement. The averaged CV for a reference tissue ranged from 5.1 % to 22.1 % for all reference tissues and observers. Centrum semiovale (range ICC 0.88–0.97) was the only reference tissue that showed excellent agreement (ICC >0.74) for all observers. Centrum semiovale showed the lowest averaged CVs for all observers (range 5.1–9.0 %). Results of the Bland-Altman analysis showed that the mean differences for centrum semiovale and putamen were close to zero. Bland-Altman plots of centrum semiovale and putamen for intra-observer variability are shown in Fig. 2. Figure 3 illustrates the effect of ROI placement and the rCBV between centrum semiovale, the frontal NAWM and parietal NAWM. The effects for this example are shown in Table 3. The difference in rCBV values between two ROIs for frontal NAWM is 21 %, and for parietal NAWM 30 % compared to 3 % for centrum semiovale.

Table 1  rCBV measurements with different reference tissues by three observers on two occasions

| Intra-observer reference tissue | Observer 1 | | Observer 2 | | Observer 3 | |
|-------------------------------|------------|---|------------|---|------------|---|
|                               | 1st evaluation | 2nd evaluation | p | 1st evaluation | 2nd evaluation | p | 1st evaluation | 2nd evaluation | p |
| NAWM by choice                | 6.1 ± 2.7   | 6.1 ± 2.9 | 0.95 | 8.2 ± 4.3   | 8.3 ± 3.3 | 0.90 | 8.5 ± 3.3   | 9.2 ± 3.8 | 0.14 |
| NAGM by choice                | 2.7 ± 1.3   | 2.7 ± 1.3 | 0.61 | 3.0 ± 1.7   | 2.6 ± 1.1 | 0.06 | 2.8 ± 1.2   | 2.6 ± 1.1 | 0.17 |
| NAWM tumor                    | 5.8 ± 2.8   | 5.1 ± 2.4 | 0.02* | 7.5 ± 4.2   | 7.9 ± 3.9 | 0.22 | 7.4 ± 4.3   | 7.8 ± 3.7 | 0.28 |
| Putamen                       | 3.3 ± 1.4   | 3.4 ± 1.7 | 0.26 | 3.3 ± 1.8   | 2.9 ± 1.3 | 0.07 | 3.1 ± 1.5   | 2.9 ± 1.3 | 0.16 |
| Frontal NAWM                 | 6.6 ± 2.8   | 6.2 ± 2.6 | 0.33 | 6.4 ± 3.0   | 6.7 ± 3.1 | 0.39 | 7.6 ± 3.1   | 7.6 ± 3.1 | 0.89 |
| Parietal NAWM                | 7.7 ± 3.8   | 7.4 ± 4.1 | 0.71 | 7.6 ± 3.7   | 8.5 ± 4.2 | 0.12 | 9.0 ± 3.8   | 8.8 ± 4.0 | 0.68 |
| Thalamus                      | 3.9 ± 1.9   | 3.7 ± 1.7 | 0.49 | 2.9 ± 1.9   | 3.1 ± 1.4 | 0.50 | 2.7 ± 1.1   | 2.5 ± 1.2 | 0.23 |
| Centrum semiovale            | 9.8 ± 3.9   | 9.7 ± 3.7 | 0.62 | 10.0 ± 4.1  | 10.7 ± 4.9 | 0.07 | 10.0 ± 3.9  | 10.1 ± 4.0 | 0.55 |

*p<0.05 was considered statistically significant.
### Table 2: Intra-observer agreement – intraclass correlation coefficient, coefficient of variation, and Bland-Altman analysis

| rCBV reference tissues | Observer 1 | | Observer 2 | | Observer 3 |
|------------------------|------------|--|------------|--|------------|
|                        | ICC   | CV   | BA          | ICC   | CV   | BA          | ICC   | CV   | BA          |
| NAWM by choice         | 0.68 (0.47–0.82) | 15.2 ± 16.6 | 0.0 ± 2.3 (–4.4–4.5) | 0.62 (0.38–0.78) | 16.2 ± 14.2 | –0.1 ± 3.4 (–6.7–6.6) | 0.71 (0.51–0.84) | 16.6 ± 16.2 | –0.7 ± 2.7 (–5.9–4.6) |
| NAGM by choice         | 0.67 (0.45–0.81) | 16.1 ± 16.6 | 0.1 ± 1.1 (–2.0–2.2) | 0.67 (0.46–0.82) | 17.0 ± 13.9 | 0.4 ± 1.1 (–1.9–2.5) | 0.86 (0.74–0.92) | 9.1 ± 12.2 | 0.1 ± 0.6 (–1.1–1.3) |
| NAWM tumor             | 0.73 (0.53–0.85) | 19.0 ± 14.7 | 0.7 ± 1.9 (–3.0–4.5) | 0.87 (0.77–0.93) | 13.0 ± 15.7 | –0.4 ± 2.0 (–4.4–3.6) | 0.88 (0.78–0.93) | 15.3 ± 18.3 | 0.3 ± 2.0 (–4.2–3.5) |
| Putamen                | 0.86 (0.75–0.93) | 11.5 ± 10.0 | –0.1 ± 0.8 (–1.8–1.5) | 0.73 (0.54–0.85) | 14.1 ± 13.8 | 0.3 ± 1.1 (–1.9–2.5) | 0.90 (0.81–0.94) | 8.5 ± 9.2 | 0.1 ± 0.6 (–1.1–1.4) |
| Frontal NAWM           | 0.68 (0.46–0.82) | 16.6 ± 14.6 | 0.3 ± 2.2 (–3.9–4.6) | 0.72 (0.53–0.84) | 19.1 ± 20.4 | –0.3 ± 2.3 (–4.8–4.1) | 0.87 (0.76–0.93) | 10.3 ± 8.8 | 0.0 ± 1.6 (–3.1–3.2) |
| Parietal NAWM          | 0.59 (0.34–0.76) | 22.1 ± 21.5 | 0.2 ± 3.6 (–6.8–7.3) | 0.61 (0.38–0.78) | 21.7 ± 20.5 | –0.9 ± 3.4 (–7.6–5.9) | 0.70 (0.50–0.83) | 13.1 ± 14.5 | 0.2 ± 3.1 (–5.8–6.2) |
| Thalamus               | 0.50 (0.22–0.70) | 21.1 ± 18.1 | 0.2 ± 1.8 (–3.3–3.7) | 0.53 (0.26–0.72) | 17.5 ± 18.5 | –0.2 ± 1.6 (–3.3–3.0) | 0.73 (0.54–0.85) | 16.8 ± 16.0 | 0.2 ± 0.8 (–1.5–1.8) |
| Centrum semiovale      | 0.92 (0.85–0.96) | 8.2 ± 9.2 | 0.1 ± 1.6 (–3.0–3.1) | 0.88 (0.79–0.94) | 9.0 ± 8.9 | –0.6 ± 2.1 (–4.8–3.5) | 0.97 (0.94–0.98) | 5.1 ± 5.4 | –0.1 ± 1.0 (–2.0–1.8) |

ICC: intraclass correlation coefficient. Numbers in parentheses are 95% confidence intervals. Data are mean CV ± standard deviations.

BA: Bland-Altman analysis. The mean difference, standard deviation and in parentheses 95% limits of agreement are shown.

NAWM: normal-appearing white matter.

### Discussion

Several factors may influence rCBV values [24], including contrast agent characteristics, acquisition technique and post-processing. A low variability of rCBV measurements is not only important for accurate tumour grading and treatment monitoring, it also enables comparisons of values across studies and patient populations.

In this study, we have shown that selecting the contralateral centrum semiovale as a reference tissue for rCBV measurements in DSC-MRI of glioma patients provides the lowest intra- and inter-observer variability. We assessed the observers’ variability of rCBV measurements and found that the centrum semiovale was easier to annotate compared to the frontal or parietal NAWM, areas which are hindered by partial volume effects of WM and GM, pronounced T2-shortening effects from vessels in the near vicinity. The centrum semiovale is a large homogeneous area of subcortical GM that is mostly visible in only one or two axial slices, and suffer less from the problems described for the frontal or parietal NAWM. This explains the excellent intraclass correlation coefficient and the low coefficient of variation. Thalamus is less suited as a reference tissue because it is more heterogeneous with nuclei and suffers from pronounced T2-shortening effects from vessels in the near vicinity. The putamen is a well-defined homogeneous area of subcortical GM and could potentially also be a good reference tissue. However, centrum semiovale showed good to excellent intra- and inter-observer agreement.

The putamen is a well-defined homogeneous area of subcortical GM and could potentially also be a good reference tissue. However, centrum semiovale showed good to excellent intra- and inter-observer agreement, and showed the lowest averaged CVs and inter-observer agreement was slightly better compared to putamen.

In this study, we have shown that selecting the contralateral centrum semiovale as a reference tissue for rCBV measurements in DSC-MRI of glioma patients provides the lowest intra- and inter-observer variability. We assessed the observers’ variability of rCBV measurements and found that the centrum semiovale was easier to annotate compared to the frontal or parietal NAWM, areas which are hindered by partial volume effects of WM and GM, pronounced T2-shortening effects from vessels in the near vicinity. The centrum semiovale is a large homogeneous area of subcortical GM that is mostly visible in only one or two axial slices, and suffer less from the problems described for the frontal or parietal NAWM. This explains the excellent intraclass correlation coefficient and the low coefficient of variation. Thalamus is less suited as a reference tissue because it is more heterogeneous with nuclei and suffers from pronounced T2-shortening effects from vessels in the near vicinity. The putamen is a well-defined homogeneous area of subcortical GM and could potentially also be a good reference tissue. However, centrum semiovale showed good to excellent intra- and inter-observer agreement, and showed the lowest averaged CVs and inter-observer agreement was slightly better compared to putamen.
Fig. 3 The region of interest (ROI) placement on the rCBV for selecting the reference tissue of centrum semiovale (A), the frontal white matter (WM) (B), and parietal WM (B). The effects of the ROI placement are shown in Table 3.

Table 3 Example of effects of two ROI placements in white matter

| Location    | Evaluation time | CBV       | rCBV     | % rCBV$_{13-42}$ |
|-------------|-----------------|-----------|----------|------------------|
| Centrum semiovale | 1. purple     | $0.34 \pm 0.050$ | $6.96$     | $100\%$         |
|             | 2. white       | $0.33 \pm 0.012$ | $7.17$     | $103\%$         |
| Frontal WM  | 1. purple      | $0.49 \pm 0.057$ | $4.88$     | $100\%$         |
|             | 2. white       | $0.62 \pm 0.158$ | $3.85$     | $79\%$          |
| Parietal WM | 1. purple      | $0.46 \pm 0.057$ | $5.18$     | $100\%$         |
|             | 2. white       | $0.66 \pm 0.068$ | $3.62$     | $70\%$          |

Table 3 shows the effects of region of interest (ROI) placement in white matter (WM) for the example in Fig. 2. The difference in rCBV values between two ROIs for frontal WM is 21 %, and for parietal WM 30 % difference compared to 3 % for centrum semiovale.
Table 4 – intraclass correlation coefficient, coefficient of variation, and Bland-Altman analysis

| rCBV Reference Tissues | Observer 1 vs. Observer 2 | Observer 2 vs. Observer 3 | Observer 1 vs. Observer 3 |
|------------------------|--------------------------|--------------------------|--------------------------|
|                        | ICC                      | CV                       | BA                       |
|                        | BA                       |                          |                           |
| NAWM by choice         | 0.44 (0.12–0.68)         | 26.3 ± 18.1              | -2.1 ± 3.6 (9.1–14.9)     |
| NAGM by choice         | 0.71 (0.27–0.83)         | 14.9 ± 14.2              | -0.2 ± 1.1 (2.9–5.3)      |
| NAWM tumour            | 0.70 (0.41–0.91)         | 16.2 ± 14.5              | 0.1 ± 1.3 (4.2–5.4)       |
| Putamen                | 0.71 (0.56–0.86)         | 15.4 ± 14.2              | 0.1 ± 1.2 (4.1–5.0)       |
| Fronto-parietal NAWM   | 0.69 (0.49–0.82)         | 20.7 ± 17.2              | -1.4 ± 2.5 (7.8–15.8)     |
| Thalamus               | 0.31 (0.02–0.62)         | 22.1 ± 17.2              | 0.1 ± 3.2 (7.2–15.8)      |
| Centrum semiovale      | 0.35 (0.07–0.55)         | 12.3 ± 10.3              | 0.3 ± 2.2 (4.6–4.6)       |

 ICC: intraclass correlation coefficient. Numbers in parentheses are 95 % confidence intervals.

CV: coefficient of variation. Data are mean CV ± standard deviations.

BA: Bland-Altman analysis. The mean difference, standard deviation, and in parentheses 95 % limits of agreement are shown.

Discussion:

Our data showed distortion artifacts due to the GE-EPI sequence, which is common near brain-bone-air interfaces, mainly in the frontal lobe and in the area of the putamen [24]. Despite these distortions, rCBV in putamen could still be calculated (see Fig. 5). Distortions in these areas can be decreased by changing the phase encoding order from posterior to anterior instead of anterior to posterior. Further research on the reproducibility of the DSC-MRI images over time is needed to investigate the distortion artifacts near the putamen and to investigate the effect of distortions on the calculation of rCBV.

Besides artifacts (like distortion artifacts and pronounced T2-shortening effects), insufficient Z-coverage can be a problem in DSC-MRI (which was not the case in our study) and centrum semiovale can be excluded from the scan. If centrum semiovale and putamen are not available for assessment then normal-appearing white matter in the slice of the tumour also showed good ICC for intra- and inter-observer variability. However, it also showed an average CV of >20 % for inter-observer variability, which is not preferable. Since artifacts are the most common occurrences to hinder normalization we advise selecting normal-appearing white matter far away from the sinuses and mastoid to avoid distortion artifacts and to stay away from vessels to avoid pronounced T2-shortening effects.

Only one related work was found that assessed the observer agreement of selecting reference tissues. Wetzel et al. [18] investigated the observer agreement of the tumour ROI and used one pixel in NAWM as reference tissue of which the exact location was not described. To analyse the precision of measurements of NAWM they selected ten ROIs close to the initial reference ROI in NAWM and showed a CV of 20 % of repeated measurements in NAWM. In our study, if NAWM is selected as reference tissue then the results showed a higher overall CV, from 23.9 % for NAWM in the slice of the tumour, 26.4 % for parietal NAWM up to 27.7 % for NAWM by choice, except for the centrum semiovale, which showed the lowest CV (range 8.1–12.5 %). Another explanation for the differences in CV (besides partial volume effects of WM and GM, pronounced T2-shortening effects or distortion artifacts) could be the size of the ROI. The use of only one pixel as reference tissue by Wetzel et al. [18] is a limitation and can explain the higher CV in their study compared to our CV for centrum semiovale since centrum semiovale is an easy to annotate homogenous area and not hindered by the problems described above. The size of the ROI is still a matter of debate, and ranges in the literature from 3.2 mm² [18] to 50 mm² [3], and even up to 432 mm² [1]. That is, size ranged from 1 pixel [18] up to 100 pixels [1]. We decided to use 25 mm² ROIs since these ROIs can be easily placed in cortical GM, but also in thalamus and putamen without partial volume averaging within the NAWM.

We chose to use circular ROIs with a fixed diameter instead of freehand ROIs for the reference tissue. In a previous preliminary study [25], we showed that the freehand ROIs were larger than the ROIs used in the current study and therefore showed lower...
CV. However, freehand ROIs showed lower agreement (lower ICC), because it is difficult to draw the same freehand ROI twice or by different observers. We therefore recommended using ROIs with fixed diameters.

Our goal was to only assess the observer agreement when selecting the reference tissue, and therefore the tumour hotspot was a fixed tumour throughout the experiments. Based on our study we cannot assess the overall influence if the observers were allowed to choose both the tumour hotspot and the reference tissue. Wetzel et al. [18] showed that the inter-observer CV for determining the tumour hotspot ROI with a fixed reference tissue ROI is 30%. Our study showed that the CV for the reference tissue with a fixed tumour hotspot ROI ranged from 8.3% to 31.1%. A study should be performed to assess the overall influence if both can freely be selected. An accepted target for measurement error in multicentre studies is a CV that is less than 20%, according to the Quantitative Imaging Biomarkers Alliance (QIBA) [26]. Our study showed a lower overall inter-observer agreement than intra-observer agreement in the rCBV measurements, which is in concordance to other studies [27–32]. However, these variabilities are difficult to compare to our results because different tumours, body parts, modalities, methods of dynamic acquisitions and pharmacokinetic models are used.

**Limitations**

One limitation of our study is that we did not use vessel segmentation in the analyses. It is known that GE-EPI sequences are more weighted towards the macrovasculature. Large vessels are pronounced due to T2 shortening outside the vessel lumen, which results in an overestimation of rCBV in cortical

---

**Fig. 5** Example of distortion artifacts in the putamen in a patient with a glioblastoma in the left hemisphere (A contrast-enhanced T1-weighted MR image, B cerebral blood volume (CBV) map from dynamic susceptibility contrast-enhanced MRI (DSC-MRI), C source DSC-MR images). Note that the CBV map is calculated, also in the putamen area. However, DSC-MR source images show distortion artifacts in the putamen area. Despite these distortions rCBV could be calculated in the putamen area.
gray matter and nearby white matter [12]. To minimize these macrovessel signals in gradient echo images vessel segmentation techniques can be used during post-processing [33].

Another limitation is that our results only apply to rCBV. Care must be taken to extrapolate the results to other perfusion parameters like cerebral blood flow, spin-echo acquisitions or other perfusion methods (like arterial spin labeling or T1-dynamic contrast-enhanced MR perfusion).

Conclusion

Our findings show that the observer variability of rCBV measurements can vary between poor and excellent, depending on the chosen reference tissue in NAWM or NAGM. Contralateral centrum semiovale as the internal reference standard for rCBV showed the lowest observer variability.

Funding The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Rashindra Manniesing.

Conflict of interest Mathias Prokop declare relationships with the following companies: Bracco, Bayer, Canon Medical Systems, Canon Medical Systems, Siemens Healthineers, Siemens Healthineers, Thirona (image processing company) and Mevis Medical Solutions). Rashindra Manniesing (as Prof Mathias Prokop) has a relationship with Canon Medical Systems Corporation (Japan, formerly known as Toshiba Medical Systems Corporation). They both received a grant from Canon. Rashindra Manniesing also received a grant from the Netherlands Organization for Scientific Research (NWO, project number: 13350). All authors of the manuscript declare they have no conflict of interest.

Statistics and biometry One of the authors has significant statistical expertise.

No complex statistical methods were necessary for this paper.

Informed consent Written informed consent was waived by the Institutional Review Board.

Ethical approval Institutional Review Board approval was obtained.

Methodology

• retrospective
• diagnostic or prognostic study
• performed at one institution

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Law M, Yang S, Wang H et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998
2. Lev MH, Ozsunar Y, Henson JW et al (2004) Glioblastoma grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214–221
3. Barajas RF Jr, Chang JS, Segal MR et al (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253:486–496
4. Mangla R, Singh G, Ziegelitz D et al (2010) Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256:575–584
5. Sawlani RN, Raizer J, Horowitz SW et al (2010) Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging–pilot study. Radiology 253:622–628
6. Essock-Burns E, Lupo JM, Cha S et al (2011) Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 13:119–131
7. Bulakbasi N, Kocaoğlu M, Farzaliyev A, Tayfun C, Ucoz T, Somuncu I (2005) Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. AJNR Am J Neuroradiol 26:2187–2199
8. Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51
9. Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 238:658–667
10. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG (2002) Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 178:711–716
11. Mangla R, Singh G, Ziegelitz D et al Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256:575–584
12. Parkes LM, Rashid W, Chard DT, Tofts PS (2004) Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Mag Reson Med 51:736–743.
13. Bedekar D, Jensen T, Schmainda KM (2010) Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. Magn Reson Med 64:907–913
14. Emblem KE, Bjornerud A (2009) An automatic procedure for normalization of cerebral blood volume maps in dynamic susceptibility contrast-based glioma imaging. AJNR Am J Neuroradiol 30:1929–1932
15. Ellingson BM, Zaw T, Cloughesy TF et al (2012) Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. J Magn Reson Imaging 35:1472–1477
16. Santarosa C, Castellano A, Conte GM et al (2016) Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel.
compartment and permeability parameters using hotspot and histogram analysis. Eur J Radiol 85:1147–1156
17. Singh R, Kesavabhotla K, Kishore SA et al (2016) Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy. AJNR Am J Neuroradiol. https://doi.org/10.3174/ajnr.A4823
18. Wetzel SG, Cha S, Johnson G et al (2002) Relative cerebral blood volume measurements in intracranial mass lesions: inter-observer and intra-observer reproducibility study. Radiology 224:797–803
19. Julia-Sape M, Lurgi M, Mier M et al (2012) Strategies for annotation and curation of translational databases: the eTUMOUR project. Database (Oxford) 2012:bas035
20. Ostergaard L (1996) High Resolution Measurement of Cerebral Blood Flow using Intravascular Tracer Bolus Passages. Part I: Mathematical Approach and Statistical Analysis. Magn Reson Imaging
21. Weisskoff RM, Boxerman JL, Sorensen AG, Kulke SM, Campbell TA, Rosen BR (1994) Simultaneous Blood Volume and Permeability Mapping using a Single Gd-Based Contrast Injection. ISMRM, San Francisco, pp 279
22. Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867
23. Oppo K, Leen E, Angerson WJ, Cooke TG, McArdle CS (1998) Doppler perfusion index: an inter-observer and intra-observer reproducibility study. Radiology 208:453–457
24. Willats L, Calamante F (2013) The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI. NMR Biomed 26:913–931
25. Oei MTH, Goraj BM, Meijer FJA et al (2012) Variability of relative cerebral blood volume normalization in patients with gliomas: interobserver and intraobserver reproducibility study. International Society for Magnetic Resonance in Medicine (ISMRM), Melbourne
26. Goh V, Schaeffter T, Leach M (2013) Reproducibility of Dynamic Contrast-enhanced MR Imaging: Why We Should Care. Radiology 266:698–700
27. Goh V, Halligan S, Hugill JA, Bassett P, Bartram CI (2005) Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intra-observer agreement. American Journal of Roentgenology 185:225–231
28. Petralia G, Preda L, Raimondi S et al (2009) Intra- and inter-observer agreement and impact of arterial input selection in perfusion CT measurements performed in squamous cell carcinoma of the upper aerodigestive tract. AJNR Am J Neuroradiol 30:1107–1115
29. Bisdas S, Surlan-Popovic K, Didanovic V, Vogl TJ (2008) Functional CT of squamous cell carcinoma in the head and neck: repeatability of tumor and muscle quantitative measurements, inter- and intra-observer agreement. Eur Radiol 18:2241–2250
30. Vos MJ, Uittehaag BM, Barkhof F et al (2003) Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 60:826–830
31. Erasmus JJ, Gladish GW, Broemeling L et al (2003) Interobserver and intra-observer variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582
32. Heye T, Merkle EM, Reiner CS et al (2013) Reproducibility of dynamic contrast-enhanced MR imaging. Part II. Comparison of intra- and inter-observer variability with manual region of interest placement versus semiautomatic lesion segmentation and histogram analysis. Radiology 266:812–821
33. Carroll TJ, Haughton VM, Rowley HA, Cordes D (2002) Confounding effect of large vessels on MR perfusion images analyzed with independent component analysis. AJNR Am J Neuroradiol 23:1007–1012